Osiris Hiccup In COPD Barely Registers In Maturing Stem Cell Sector
The rapidly evolving stem cell space may have matured to the level where a single company's misstep no longer raises questions about the viability of the whole endeavor. At least that seems to be the reaction following the mixed results of Osiris Therapeutics' Prochymal stem cell therapy in an interim look at a study in chronic obstructive pulmonary disease.
You may also be interested in...
Every so often an undeniably important technology emerges resulting in the consolidation of IP and the alignment of thought leaders around a few main players. The new battleground is stem cells. And though the two heavy hitters in the promising induced pluripotent stem (iPS) cell space, Ipierian and Fate Therapeutics, are perhaps less aggressive in publicly asserting their dominance, they've positioned themselves as leading competitors in the still-nascent but rapidly advancing area of cellular reprogramming.
New guidance explains how UK-based sites and organizations can facilitate routine on-site good practice inspections that are due to restart next month.
Nidda Healthcare, the investment vehicle controlled by Bain Capital and Cinven, has decided on a share price for the final squeeze-out of Stada’s remaining minority shareholders.